Advertisement
Person › Details
Rémi Delansorne (Hybrigenics S.A. (Euronext Paris: ALHYG))
Delansorne, Rémi (Hybrigenics 201110 CEO)
Organisation | Hybrigenics S.A. (Euronext Paris: ALHYG) | |
Group | Hybrigenics (Group) | |
Product | drug discovery | |
Record changed: 2018-10-24 |
Advertisement
More documents for Rémi Delansorne
- [1] Hybrigenics S.A.. (10/23/18). "Press Release: Clinical Study of Inecalcitol in Acute Myeloid Leukemia Stopped for Futility. The Clinical Development of Inecalcitol Is Discontinued". Paris....
- [2] Hybrigenics S.A.. (2/19/18). "Press Release: Hybrigenics Completes Its Strategic Refocusing on Biopharmaceutical R&D. Management Buy-out of Helixio Business Unit Dedicated to Genomic Services". Paris....
- [3] Hybrigenics S.A.. (4/28/17). "Press Release: Hybrigenics Full Year 2016 Results". Paris....
- [4] Hybrigenics S.A.. (3/13/17). "Press Release: Strategic Refocusing on Biopharmaceutical R&D". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top